Wegovy’s supply + brewing competition concerns overshadow a decent Q2
04/08/22 -"In Q2, Novo continued its strong run, driven by strong growth momentum seen in both Obesity and GLP-1 Diabetes franchise. However, emerging and potential competition from Eli Lilly’s Mounjaro in ..."
Pages
65
Language
English
Published on
04/08/22
You may also be interested by these reports :
10/08/26
The Q2 results exceeded expectations, driven by a healthy showing for the Life Science and Electronics businesses, whereas Healthcare continued to ...
07/08/26
Genmab’s Q2 performance exceeded expectations. The blood cancer drug Darzalex demonstrated strong results, with other drugs also showing solid ...
05/08/26
The Q2 results exceeded expectations, aided by sustained strong uptake for the Wegovy pill (obesity). Consequently, the management upgraded its ...
04/08/26
BioNTech reported a disappointing quarter, with sales significantly below forecasts and operating losses exceeding expectations. Weaker Covid-19 ...